What if the trick to getting cancer immunotherapy to parts of the world that can’t access it is simply lowering the dose? A ...

Read more about ASCO results showing improved survival with TMC-I in recurrent or metastatic head and neck cancer.

A prospective, single-arm, phase II study of adebrelimab plus carboplatin and albumin-bound taxanol as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell ...

Regimen showed benefit in advanced head and neck cancer ...

Prognosis is extremely poor for patients with head and neck squamous cell carcinoma (HNSCC), which accounts for around 90% of all head and neck cancer. Especially in the more aggressive subtype of ...

Head and neck squamous cell carcinoma (HNSCC) remains a globally prevalent malignancy with high morbidity and mortality. Despite therapeutic advances, patient outcomes are hindered by tumor ...

Head and neck cancer is the sixth most common cancer worldwide, and it affects around 12,800 people in the UK each year.

Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.